CDEK
← All drugs Report issue

terbogrel

Small moleculeexperimental

Terbogrel (INN) is an experimental drug that has been studied for its potential to prevent the vasoconstricting and platelet-aggregating action of thromboxanes. Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A synthase inhibitor. The drug was developed by Boehringer Ingelheim. — Wikipedia

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 1998 (NCT02223000)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Thromboxane A2 receptorANTAGONIST

    TBXA2R antagonist

    Terbogrel mode of action combines the inhibition of the thromboxane A2 (TxA2) receptor with the inhibition of thromboxane A synthase. This combination not only blocks the formation and action of TxA2, but it also leads to an enhanced local production of antithrombotic prostaglandins. This mechanism provides potent antithrombotic action without affecting systemic haemostasis.

  • Thromboxane-A synthaseINHIBITOR

    TBXAS1 inhibitor

    Terbogrel mode of action combines the inhibition of the thromboxane A2 (TxA2) receptor with the inhibition of thromboxane A synthase. This combination not only blocks the formation and action of TxA2, but it also leads to an enhanced local production of antithrombotic prostaglandins. This mechanism provides potent antithrombotic action without affecting systemic haemostasis.

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)N/C(=N\C#N)Nc1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1
Mol. weight
405.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (5e)-6-(m-(3-tert-butyl-2-cyanoguanidino)phenyl)-6-(3-pyridyl)-5-hexenoic acid
  • 6-(3-(((cyanoamino)((1,1-dimethylethyl)amino)methylene)amino)phenyl)-6-(3-pyridinyl)hexenoic acid
  • bibv 308
  • bibv 308
  • bibv-308-se
  • bibv-308-se
  • terbogrel
  • terbogrel
  • terbogrel
  • terbogrel
  • terbogrel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02223013Phase 1Apr 1, 1999Boehringer Ingelheim
NCT02222987Phase 1Feb 1, 1999Boehringer Ingelheim
NCT02223494Phase 2Oct 1, 1998Boehringer Ingelheim
NCT02223481Phase 2May 1, 1998Boehringer Ingelheim
NCT02223000Phase 1Mar 1, 1998Boehringer Ingelheim
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit5521998
1 organizations
Page 1 / 1